People · Operator

Michael J Groh, PharmD

Named in public records as an officer, director or promoter · active 2015–2015 · Other Technology

1
Companies
5
Filings
$15.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Edlogics, LLCOther TechnologySeries A$15.0M$406.0M2015
Operator network

Michael J Groh, PharmD at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Tommy G. Thompson · 7 companies · 1 sharedTommy G. ThompsonDavid L. Bernd · 3 companies · 1 sharedDavid L. BerndDavid Ann Kaufman · 1 companies · 1 sharedDavid Ann KaufmanJerry T. Gulley II · 1 companies · 1 sharedJerry T. Gulley IIKenneth Ann Melani · 1 companies · 1 sharedKenneth Ann MelaniKirk T. Woodruff, MAOD · 1 companies · 1 sharedKirk T. Woodruff,…Mary Ann Cope, R.Ph. · 1 companies · 1 sharedMary Ann Cope, R.…Scott W. Reed · 1 companies · 1 sharedScott W. ReedSteven F. Bauwens · 1 companies · 1 sharedSteven F. BauwensSteven F. Bauwens, PhD · 1 companies · 1 sharedSteven F. Bauwens…Thomas Chamberlain, Pharm.D. · 1 companies · 1 sharedThomas Chamberlai…Thomas Chamberlain, PharmD · 1 companies · 1 sharedThomas Chamberlai…Edlogics, LLC · $15.0M raisedEdlogics, LLCMichael J Groh, PharmDMP
Michael J Groh, PharmD Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Michael J Groh, PharmD on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Tommy G. Thompson17
David L. Bernd13
Steven F. Bauwens11
Thomas Chamberlain, Pharm.D.11
Mary Ann Cope, R.Ph.11
Scott W. Reed11
Thomas Chamberlain, PharmD11
Kenneth Ann Melani11
David Ann Kaufman11
Steven F. Bauwens, PhD11
Kirk T. Woodruff, MAOD11
Jerry T. Gulley II11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.